Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Pharmacy · PA · Rheumatology, Critical Care, Infectious Disease +2 moreMedium impact

08.00.85t, Tocilizumab and Related Biosimilars for Intravenous Infusion

Act
by Jul 1, 2026
Effective date
Jul 1, 2026
Identified
Jul 23, 2026

Summary

Independence Blue Cross updated policy 08.00.85t to 08.00.85u, designating tocilizumab-anoh (Avtozma) as an additional preferred product alongside tocilizumab-aazg (Tyenne), and added three new HCPCS codes (M0231, M0232, Q0234) for tocilizumab-bavi COVID-19 treatment. Billing teams must recognize these preferred products to apply correct reimbursement levels and use the new codes for eligible COVID-19 claims.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Jul 1, 2026 · 5 steps
01Billing team must update billing software to recognize tocilizumab-anoh (Avtozma IV) as a preferred product with the same reimbursement tier as tocilizumab-aazg (Tyenne IV).
02Add new HCPCS codes M0231, M0232, and Q0234 to the system for COVID-19 claims.
03Update clinical documentation templates to clarify when to use these codes versus J3262.
04Ensure claims for non-preferred tocilizumab products (Actemra IV, Tofidence IV, other biosimilars) are flagged for prior authorization review unless documentation shows contraindication, intolerance, or inadequate response to preferred products.
05Train billing staff on the distinction between preferred and non-preferred products to prevent claim denials.

Codes mentioned

J3262M0231M0232Q0234

Original notice

08.00.85t, Tocilizumab and Related Biosimilars for Intravenous Infusion
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.045q, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous InjectionMediumEffective Jul 1, 2026 · Pharmacy08.00.85u, Tocilizumab and Related Biosimilars for Intravenous InfusionHighEffective Sep 14, 2026 · Pharmacy08.00.85r, Tocilizumab and Related Biosimilars for Intravenous InfusionHighEffective Oct 1, 2025 · Pharmacy08.00.85s, Tocilizumab and Related Biosimilars for Intravenous InfusionMediumEffective Apr 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesPA policy changesRheumatologyCritical CareInfectious DiseaseHematologyPharmacyCode J3262Code M0231Code M0232Code Q0234

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account